Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289143 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 457
- Enrollment target
NCT03289143 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 457 participants.
The verdict
NCT03289143, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 457 participants
- Enrollment target
Study Summary
This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period was available to participants who completed the double-blind treatment period and who, in the judgment of the investigator, would potentially benefit from open-label Semorinemab treatment.
Interventions
- DRUG Placebo
- DRUG [18F]GTP1
- DRUG Semorinemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289143
The ClinicalTrials.gov registry entry for NCT03289143 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03289143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289143 about?
NCT03289143 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease". This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period was available to participants who completed the double-blind treatmen...
What is the current status of trial NCT03289143?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 457 participants. The study started on 2017-10-04. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT03289143?
The interventions under investigation include: Placebo (DRUG), [18F]GTP1 (DRUG), Semorinemab (DRUG).
Who is sponsoring clinical trial NCT03289143?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.